Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Clinical Significance of Plasma Apolipoprotein-AII Isoforms as a Marker of Pancreatic Exocrine Disorder for Patients with Pancreatic Adenocarcinoma Undergoing Chemoradiotherapy, Paying Attention to Pancreatic Morphological Changes.

Hayasaki A, Murata Y, Usui M, Hibi T, Fujii T, Iizawa Y, Kato H, Tanemura A, Azumi Y, Kuriyama N, Kishiwada M, Mizuno S, Sakurai H, Uchida K, Isaji S.

Biomed Res Int. 2019 Apr 4;2019:5738614. doi: 10.1155/2019/5738614. eCollection 2019.

2.

Prognostic Nutritional Index After Chemoradiotherapy Was the Strongest Prognostic Predictor Among Biological and Conditional Factors in Localized Pancreatic Ductal Adenocarcinoma Patients.

Ichikawa K, Mizuno S, Hayasaki A, Kishiwada M, Fujii T, Iizawa Y, Kato H, Tanemura A, Murata Y, Azumi Y, Kuriyama N, Usui M, Sakurai H, Isaji S.

Cancers (Basel). 2019 Apr 10;11(4). pii: E514. doi: 10.3390/cancers11040514.

3.

The clinical impact of portal venous patency ratio on prognosis of patients with pancreatic ductal adenocarcinoma undergoing pancreatectomy with combined resection of portal vein following preoperative chemoradiotherapy.

Jaseanchiun W, Kato H, Hayasaki A, Fujii T, Iizawa Y, Tanemura A, Murata Y, Azumi Y, Kuriyama N, Kishiwada M, Mizuno S, Usui M, Sakurai H, Isaji S.

Pancreatology. 2019 Mar;19(2):307-315. doi: 10.1016/j.pan.2019.01.020. Epub 2019 Jan 25.

PMID:
30738764
4.

Comparative Study Between Gemcitabine-Based and Gemcitabine Plus S1-Based Preoperative Chemoradiotherapy for Localized Pancreatic Ductal Adenocarcinoma, With Special Attention to Initially Locally Advanced Unresectable Tumor.

Takeuchi T, Mizuno S, Murata Y, Hayasaki A, Kishiwada M, Fujii T, Iizawa Y, Kato H, Tanemura A, Kuriyama N, Azumi Y, Usui M, Sakurai H, Isaji S.

Pancreas. 2019 Feb;48(2):281-291. doi: 10.1097/MPA.0000000000001227.

PMID:
30629019
5.

The Critical Role of Biliary Candidiasis in Development of Surgical Site Infections after Pancreatoduodenectomy: Results of Prospective Study Using a Selective Culture Medium for Candida Species.

Kato H, Iizawa Y, Nakamura K, Gyoten K, Hayasaki A, Fujii T, Murata Y, Tanemura A, Kuriyama N, Azumi Y, Kishiwada M, Mizuo S, Usui M, Sakurai H, Isaji S.

Biomed Res Int. 2018 Nov 18;2018:5939724. doi: 10.1155/2018/5939724. eCollection 2018.

6.

Isolated Biliary Fistula After Donor Right Hepatectomy and Its Novel Interventional Treatment: Isolated Liver-Punctured Drainage.

Kato H, Usui M, Nakatsuka A, Hayasaki A, Ito T, Iizawa Y, Murata Y, Tanemura A, Kuriyama N, Azumi Y, Kishiwada M, Mizuno S, Sakurai H, Isaji S.

Transplant Proc. 2018 Nov;50(9):2885-2888. doi: 10.1016/j.transproceed.2018.03.032. Epub 2018 Mar 16.

PMID:
30401417
7.

Recombinant Human Soluble Thrombomodulin Attenuates Hepatic Ischemia and/or Reperfusion Injury by Inhibiting Leukocyte Accumulation in Mice With Normal and Fatty Liver.

Fujii T, Kuriyama N, Hayasaki A, Iizawa Y, Tanemura A, Kato H, Murata Y, Azumi Y, Kishiwada M, Mizuno S, Usui M, Sakurai H, Isaji S.

Transplant Proc. 2018 Nov;50(9):2807-2814. doi: 10.1016/j.transproceed.2018.03.044. Epub 2018 Mar 15.

PMID:
30401402
8.

Biliary Complications During and After Donor Hepatectomy in Living Donor Liver Transplantation Focusing on Characteristics of Biliary Leakage and Treatment for Intraoperative Bile Duct Injury.

Tanemura A, Mizuno S, Hayasaki A, Fujii T, Iizawa Y, Kato H, Murata Y, Kuriyama N, Azumi Y, Kishiwada M, Usui M, Sakurai H, Isaji S.

Transplant Proc. 2018 Nov;50(9):2705-2710. doi: 10.1016/j.transproceed.2018.03.045. Epub 2018 Mar 15.

PMID:
30401381
9.

De Novo Malignancy Following Adult-to-Adult Living Donor Liver Transplantation Focusing on Posttransplantation Lymphoproliferative Disorder.

Mizuno S, Hayasaki A, Ito T, Fujii T, Iizawa Y, Kato H, Murata Y, Tanemura A, Kuriyama N, Azumi Y, Kishiwada M, Usui M, Sakurai H, Isaji S.

Transplant Proc. 2018 Nov;50(9):2699-2704. doi: 10.1016/j.transproceed.2018.03.059. Epub 2018 Mar 15.

PMID:
30401380
10.

Early Enteral Feeding of Daikenchuto Stimulates Early Bowel Movement With Increased Portal Venous Blood Flow After Living Donor Liver Transplantation.

Usui M, Hayasaki A, Fujii T, Iizawa Y, Kato H, Tanemura A, Murata Y, Azumi Y, Kuriyama N, Kishiwada M, Mizuno S, Sakurai H, Isaji S.

Transplant Proc. 2018 Nov;50(9):2690-2694. doi: 10.1016/j.transproceed.2018.03.037. Epub 2018 Mar 16.

PMID:
30401378
11.

Intravenous Administration of Tacrolimus Stabilizes Control of Blood Concentration Regardless of CYP3A5 Polymorphism in Living Donor Liver Transplantation: Comparison of Intravenous Infusion and Oral Administration in Early Postoperative Period.

Kato H, Usui M, Muraki Y, Okuda M, Nakatani K, Hayasaki A, Ito T, Iizawa Y, Murata Y, Tanemura A, Kuriyama N, Azumi Y, Kishiwada M, Mizuno S, Sakurai H, Isaji S.

Transplant Proc. 2018 Nov;50(9):2684-2689. doi: 10.1016/j.transproceed.2018.03.049. Epub 2018 Mar 15.

PMID:
30401377
12.

Feasibility and Outcomes of Direct Dual Portal Vein Anastomosis in Living Donor Liver Transplantation Using the Right Liver Graft With Anatomic Portal Vein Variations.

Kuriyama N, Tanemura A, Hayasaki A, Fujii T, Iizawa Y, Kato H, Murata Y, Azumi Y, Kishiwada M, Mizuno S, Usui M, Sakurai H, Isaji S.

Transplant Proc. 2018 Nov;50(9):2640-2644. doi: 10.1016/j.transproceed.2018.03.053. Epub 2018 Mar 15.

PMID:
30401366
13.

Clinical Significance of Histological Effect and Intratumor Stromal Expression of Tenascin-C in Resected Specimens After Chemoradiotherapy for Initially Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma.

Hayasaki A, Murata Y, Usui M, Hibi T, Ito T, Iizawa Y, Kato H, Tanemura A, Azumi Y, Kuriyama N, Kishiwada M, Mizuno S, Sakurai H, Yoshida T, Isaji S.

Pancreas. 2018 Apr;47(4):390-399. doi: 10.1097/MPA.0000000000001022.

PMID:
29517632
14.

Survival Analysis in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Chemoradiotherapy Followed by Surgery According to the International Consensus on the 2017 Definition of Borderline Resectable Cancer.

Hayasaki A, Isaji S, Kishiwada M, Fujii T, Iizawa Y, Kato H, Tanemura A, Murata Y, Azumi Y, Kuriyama N, Mizuno S, Usui M, Sakurai H.

Cancers (Basel). 2018 Mar 5;10(3). pii: E65. doi: 10.3390/cancers10030065.

15.

Platelet Activation Assessed by Glycoprotein VI/Platelet Ratio Is Associated With Portal Vein Thrombosis After Hepatectomy and Splenectomy in Patients With Liver Cirrhosis.

Matsui T, Usui M, Wada H, Iizawa Y, Kato H, Tanemura A, Murata Y, Kuriyama N, Kishiwada M, Mizuno S, Sakurai H, Isaji S.

Clin Appl Thromb Hemost. 2018 Mar;24(2):254-262. doi: 10.1177/1076029617725600. Epub 2017 Oct 19.

16.

Long-term outcomes after pancreaticoduodenectomy using pair-watch suturing technique: Different roles of pancreatic duct dilatation and remnant pancreatic volume for the development of pancreatic endocrine and exocrine dysfunction.

Iizawa Y, Kato H, Kishiwada M, Hayasaki A, Tanemura A, Murata Y, Azumi Y, Kuriyama N, Mizuno S, Usui M, Sakurai H, Isaji S.

Pancreatology. 2017 Sep - Oct;17(5):814-821. doi: 10.1016/j.pan.2017.06.008. Epub 2017 Jun 23.

17.

Incidence and Risk Factors of Postoperative Delirium following Pancreatic Surgery: Does the Administration of TJ-54 Reduce the Incidence of Delirium.

Mizuno S, Takeuchi S, Kishiwada M, Mizutani N, Matsuda M, Sekoguchi N, Iizawa Y, Azumi Y, Kuriyama N, Usui M, Sakurai H, Maruyama K, Okuda M, Okada M, Isaji S.

Dig Surg. 2018;35(1):1-10. doi: 10.1159/000456627. Epub 2017 Feb 8.

PMID:
28171868
18.

Pretransplant Serum Hyaluronic Acid Can Be a Biomarker as a Prognostic Predictor in Adult-to-Adult Living Donor Liver Transplantation.

Mizuno S, Das BC, Iizawa Y, Kato H, Murata Y, Tanemura A, Kuriyama N, Azumi Y, Kishiwada M, Usui M, Sakurai H, Isaji S.

Transplant Proc. 2017 Jan - Feb;49(1):102-108. doi: 10.1016/j.transproceed.2016.11.019.

PMID:
28104115
19.

Transhepatic Hilar Approach for Perihilar Cholangiocarcinoma: Significance of Early Judgment of Resectability and Safe Vascular Reconstruction.

Kuriyama N, Isaji S, Tanemura A, Iizawa Y, Kato H, Murata Y, Azumi Y, Kishiwada M, Mizuno S, Usui M, Sakurai H.

J Gastrointest Surg. 2017 Mar;21(3):590-599. doi: 10.1007/s11605-016-3332-7. Epub 2016 Nov 28.

20.

Negative Impact of Biliary Candidiasis on Early and Late Postoperative Complications After Pancreatoduodenectomy Usefulness of the CHROMagar Candida Plate for Identification.

Kato H, Iizawa Y, Kishiwada M, Usui M, Nakamura A, Murata Y, Tanemura A, Kuriyama N, Azumi Y, Mizuno S, Sakurai H, Isaji S.

Pancreas. 2016 Oct;45(9):e45-7. doi: 10.1097/MPA.0000000000000682. No abstract available.

PMID:
27623557
21.

Impact of Splenectomy Just Before Partial Orthotopic Liver Transplantation Using Small-for-Size Graft in Rats.

Kuriyama N, Iizawa Y, Kato H, Murata Y, Tanemura A, Azumi Y, Kishiwada M, Mizuno S, Usui M, Sakurai H, Isaji S.

Transplant Proc. 2016 May;48(4):1304-8. doi: 10.1016/j.transproceed.2016.02.041. Erratum in: Transplant Proc. 2017 May;49(4):916.

PMID:
27320610
22.

Living Donor Liver Transplantation for Biliary Atresia With Severe Preduodenal Portal Vein Stricture: Success and Pitfall of Portal Vein Reconstruction.

Kato H, Usui M, Iizawa Y, Tanemura A, Murata Y, Kuriyama N, Kishiwada M, Mizuno S, Sakurai H, Inoue M, Uchida K, Isaji S.

Transplant Proc. 2016 May;48(4):1218-20. doi: 10.1016/j.transproceed.2016.01.029.

PMID:
27320591
23.

Influence of Angiotensin-converting Enzyme Genetic Polymorphism on Late Renal Dysfunction After Adult-to-adult Living-donor Liver Transplantation.

Matsui T, Usui M, Fujinaga K, Nakatani K, Iizawa Y, Kato H, Tanemura A, Murata Y, Azumi Y, Kuriyama N, Kishiwada M, Mizuno S, Sakurai H, Isaji S.

Transplant Proc. 2016 May;48(4):1184-9. doi: 10.1016/j.transproceed.2016.02.014.

PMID:
27320583
24.

Detection of uranium and chemical state analysis of individual radioactive microparticles emitted from the Fukushima nuclear accident using multiple synchrotron radiation X-ray analyses.

Abe Y, Iizawa Y, Terada Y, Adachi K, Igarashi Y, Nakai I.

Anal Chem. 2014 Sep 2;86(17):8521-5. doi: 10.1021/ac501998d. Epub 2014 Aug 15.

PMID:
25084242
25.
26.

Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model.

Takashima K, Matsunaga N, Yoshimatsu M, Hazeki K, Kaisho T, Uekata M, Hazeki O, Akira S, Iizawa Y, Ii M.

Br J Pharmacol. 2009 Aug;157(7):1250-62. doi: 10.1111/j.1476-5381.2009.00297.x. Epub 2009 Jun 25.

27.

Primary non-Hodgkin's lymphoma of the gallbladder diagnosed by laparoscopic cholecystectomy.

Kato H, Naganuma T, Iizawa Y, Kitagawa M, Tanaka M, Isaji S.

J Hepatobiliary Pancreat Surg. 2008;15(6):659-63. doi: 10.1007/s00534-007-1283-9. Epub 2008 Nov 7.

PMID:
18987940
28.

TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain.

Kawamoto T, Ii M, Kitazaki T, Iizawa Y, Kimura H.

Eur J Pharmacol. 2008 Apr 14;584(1):40-8. doi: 10.1016/j.ejphar.2008.01.026. Epub 2008 Feb 5.

PMID:
18299127
29.

Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model.

Sha T, Sunamoto M, Kitazaki T, Sato J, Ii M, Iizawa Y.

Eur J Pharmacol. 2007 Oct 1;571(2-3):231-9. Epub 2007 Jun 29.

PMID:
17632100
30.

Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.

Imamura S, Ichikawa T, Nishikawa Y, Kanzaki N, Takashima K, Niwa S, Iizawa Y, Baba M, Sugihara Y.

J Med Chem. 2006 May 4;49(9):2784-93.

PMID:
16640339
31.

Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.

Seto M, Aikawa K, Miyamoto N, Aramaki Y, Kanzaki N, Takashima K, Kuze Y, Iizawa Y, Baba M, Shiraishi M.

J Med Chem. 2006 Mar 23;49(6):2037-48.

PMID:
16539392
32.
33.

TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans.

Baba M, Takashima K, Miyake H, Kanzaki N, Teshima K, Wang X, Shiraishi M, Iizawa Y.

Antimicrob Agents Chemother. 2005 Nov;49(11):4584-91.

34.

Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.

Takashima K, Miyake H, Kanzaki N, Tagawa Y, Wang X, Sugihara Y, Iizawa Y, Baba M.

Antimicrob Agents Chemother. 2005 Aug;49(8):3474-82.

35.

CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological evaluation of piperidine-4-carboxamide derivatives.

Imamura S, Nishikawa Y, Ichikawa T, Hattori T, Matsushita Y, Hashiguchi S, Kanzaki N, Iizawa Y, Baba M, Sugihara Y.

Bioorg Med Chem. 2005 Jan 17;13(2):397-416.

PMID:
15598561
36.

Orally active CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological activities of 1-benzazepine derivatives containing a sulfoxide moiety.

Seto M, Miyamoto N, Aikawa K, Aramaki Y, Kanzaki N, Iizawa Y, Baba M, Shiraishi M.

Bioorg Med Chem. 2005 Jan 17;13(2):363-86.

PMID:
15598559
37.

In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599.

Iizawa Y, Nagai J, Ishikawa T, Hashiguchi S, Nakao M, Miyake A, Okonogi K.

J Infect Chemother. 2004 Jun;10(3):146-56.

PMID:
15290453
38.

Orally active CCR5 antagonists as anti-HIV-1 agents 2: synthesis and biological activities of anilide derivatives containing a pyridine N-oxide moiety.

Seto M, Aramaki Y, Imoto H, Aikawa K, Oda T, Kanzaki N, Iizawa Y, Baba M, Shiraishi M.

Chem Pharm Bull (Tokyo). 2004 Jul;52(7):818-29.

39.

Orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activity of 1-benzothiepine 1,1-dioxide and 1-benzazepine derivatives containing a tertiary amine moiety.

Seto M, Aramaki Y, Okawa T, Miyamoto N, Aikawa K, Kanzaki N, Niwa S, Iizawa Y, Baba M, Shiraishi M.

Chem Pharm Bull (Tokyo). 2004 May;52(5):577-90.

40.

CCR5 antagonists as anti-HIV-1 agents. Part 2: Synthesis and biological evaluation of N-[3-(4-benzylpiperidin-1-yl)propyl]-N,N'-diphenylureas.

Imamura S, Kurasawa O, Nara Y, Ichikawa T, Nishikawa Y, Iida T, Hashiguchi S, Kanzaki N, Iizawa Y, Baba M, Sugihara Y.

Bioorg Med Chem. 2004 May 1;12(9):2295-306.

PMID:
15080927
41.

CCR5 antagonists as anti-HIV-1 agents. 1. Synthesis and biological evaluation of 5-oxopyrrolidine-3-carboxamide derivatives.

Imamura S, Ishihara Y, Hattori T, Kurasawa O, Matsushita Y, Sugihara Y, Kanzaki N, Iizawa Y, Baba M, Hashiguchi S.

Chem Pharm Bull (Tokyo). 2004 Jan;52(1):63-73.

43.

TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties.

Ishikawa T, Matsunaga N, Tawada H, Kuroda N, Nakayama Y, Ishibashi Y, Tomimoto M, Ikeda Y, Tagawa Y, Iizawa Y, Okonogi K, Hashiguchi S, Miyake A.

Bioorg Med Chem. 2003 May 29;11(11):2427-37.

PMID:
12735989
44.

In vitro and in vivo antifungal activities of TAK-456, a novel oral triazole with a broad antifungal spectrum.

Tsuchimori N, Hayashi R, Kitamoto N, Asai K, Kitazaki T, Iizawa Y, Itoh K, Okonogi K.

Antimicrob Agents Chemother. 2002 May;46(5):1388-93.

45.

Efficacy of TAK-457, a novel intravenous triazole, against invasive pulmonary Aspergillosis in neutropenic mice.

Hayashi R, Kitamoto N, Iizawa Y, Ichikawa T, Itoh K, Kitazaki T, Okonogi K.

Antimicrob Agents Chemother. 2002 Feb;46(2):283-7.

46.

Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.

Takashima K, Miyake H, Furuta RA, Fujisawa JI, Iizawa Y, Kanzaki N, Shiraishi M, Okonogi K, Baba M.

Antimicrob Agents Chemother. 2001 Dec;45(12):3538-43.

47.

Studies on anti-MRSA parenteral cephalosporins. IV. A novel water-soluble N-phosphono type prodrug for parental administration.

Ishikawa T, Nakayama Y, Tomimoto M, Niwa SI, Kamiyama K, Hashiguchi S, Iizawa Y, Okonogi K, Miyake A.

J Antibiot (Tokyo). 2001 Apr;54(4):364-74.

48.
49.

[Prospect for the development of antibacterial agents with new mode of action].

Iizawa Y.

Nihon Rinsho. 2001 Apr;59(4):795-800. Review. Japanese.

PMID:
11305009
50.

Supplemental Content

Loading ...
Support Center